<img height="1" width="1" style="display:none;" alt="" src="https://px.ads.linkedin.com/collect/?pid=384506&amp;fmt=gif">
Skip to content
Search
Book a Demo
    Book a Demo

      The Plan to End Aging

      Thursday August 6, 2026 9 AM (PT) | 12 PM (ET) | 6 PM (CEST)

      Reserve Your Webinar Seat

      Advances in biotechnology are changing how we think about aging. From AI-driven drug discovery to emerging therapeutic approaches, researchers and innovators are exploring new ways to extend healthy lifespan and accelerate the development of longevity therapies.

      Join Omri Amirav Drory, General Partner at NFX Capital ($1.4B AUM), as he shares his vision for the future of longevity biotechnology and the technologies and companies driving the race to 160. Drawing on his experience investing at the intersection of technology and biology, Omri will discuss the innovations shaping the next generation of longevity research and what they could mean for the future of healthcare.

      Topics include:

      • The current state of longevity biotechnology

      • Emerging technologies advancing longevity research

      • Companies pushing the frontier of longevity biotech

      • The Race to 160 and the vision for extending healthy lifespan

      • Investment trends driving innovation in the longevity ecosystem

      • What's next for the future of aging research

      Who Should Attend

      This session is intended for biotechnology and pharmaceutical professionals, longevity researchers, investors, startup founders, and drug discovery scientists interested in the technologies, companies, and investment trends shaping the future of longevity biotechnology.

      Reserve your spot today!
      Omri Amirav Drory's headshot

      Omri Amirav Drory

      General Partner, NFX Capital

      Omri Amirav-Drory, Ph.D. is the General Partner at NFX Bio. He is a scientist and an operator who has founded, scaled, and invested in some of today’s most important techbio companies.   Before becoming an investor, Omri was the Founding CEO of Genome Compiler, which developed software for genetic engineers and molecular and synthetic biologists. He led the company to a successful acquisition by Twist Bioscience, a next-generation DNA synthesis company currently valued at ~$2.5 Billion. Omri stayed at Twist for almost three years after the acquisition as the Head of Corporate Development.   After leaving Twist, Omri became the Founding Partner at Tech.Bio where he invested and advised in companies like Mammoth Biosciences, immunai, C2i Genomics, and more. Now as an investor, Omri understands what it means to be a Scientist-CEO and is committed to a future where this is the norm, not the exception.

      LinkedIn